Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Sales

Foghorn Therapeutics (FHTX) EBIT Margin (2020 - 2025)

Foghorn Therapeutics has reported EBIT Margin over the past 6 years, most recently at 258.22% for Q4 2025.

  • Quarterly results put EBIT Margin at 258.22% for Q4 2025, up 58229.0% from a year ago — trailing twelve months through Dec 2025 was 279.49% (up 17481.0% YoY), and the annual figure for FY2025 was 279.49%, up 17481.0%.
  • EBIT Margin for Q4 2025 was 258.22% at Foghorn Therapeutics, down from 226.92% in the prior quarter.
  • Over the last five years, EBIT Margin for FHTX hit a ceiling of 97.73% in Q3 2023 and a floor of 64051.22% in Q3 2021.
  • Median EBIT Margin over the past 5 years was 565.36% (2023), compared with a mean of 4597.06%.
  • Biggest five-year swings in EBIT Margin: tumbled -5372217bps in 2021 and later soared 6362525bps in 2022.
  • Foghorn Therapeutics' EBIT Margin stood at 3938.57% in 2021, then soared by 81bps to 762.09% in 2022, then soared by 42bps to 441.29% in 2023, then tumbled by -90bps to 840.51% in 2024, then skyrocketed by 69bps to 258.22% in 2025.
  • The last three reported values for EBIT Margin were 258.22% (Q4 2025), 226.92% (Q3 2025), and 279.17% (Q2 2025) per Business Quant data.